Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC) -- Ignore unavailable to you. Want to Upgrade?

To: Profiteer who wrote (50)	6/5/1998 12:57:00 PM
From: Gwolf	Read Replies (1) \| Respond to of 5402

Chirodoc, That wording is very standard. One thing the SEC wants companies to do is give full disclosure and they require that it be presented with the most negative possible outcome so that investors will have their eyes open when they invest. If you look at the same material for any Biotech company they read the same. Most of the high flying Biotechs do not make a dime, it is the anticipation that they will finally have a major product take off that keeps the stocks going. The contract that we are waiting for will provide them with the funding they need to get the animal testing started. If the animal testing is successful then they won't need to worry about funding for the human trials because they will have major drug companies ready to throw money at them for the next stage. Remeber one thing their original product was tested on humans and received a patent. This is the next generation , so if the first one worked on humans you can make an assumption that the newer version will work even better and certainly should work on animals. Gwolf

To: Profiteer who wrote (50)	6/5/1998 3:09:00 PM
From: Prospector	Read Replies (1) \| Respond to of 5402

PROF---- HOLLY COW... Them thar Baxter people are-a spendin a ton of money to find the right vein of gold (BLOOD SUBSTITUTE ) Looks like Baxters old claim just turned to PI-RITE.. OLD DR DREES better be ready ,,, Those thar Baxter Brothers just might be knockin on his DOOR... Prospector

To: Profiteer who wrote (50)	6/6/1998 11:28:00 AM
From: chirodoc	Read Replies (1) \| Respond to of 5402

Several other companies, both domestic and foreign, are working to develop alternatives to human blood. They include: Alliance Pharmaceutical Corporation (San Diego, California); Baxter International (Deerfield, Illinois); Biopure Corporation (Boston, Massachusetts); Northfield Labs (Chicago, Illinois); and Somatogen Corporation (Boulder, Colorado). These competitors are involved in the development of a wide variety of human blood substitutes, including synthetic compounds, recycled human blood and recombinant hemoglobin. Neither the list of competitors nor the list of human blood substitutes is exhaustive. Furthermore, many of the Company's existing or potential competitors have significantly greater technical and financial resources than the Company and may be better able to develop, test, produce and market products. These competitors may develop products that are competitive with or better than the Company's product and that may render the Company's product obsolete. The Company can provide no assurance that it will be able to compete successfully.